Abbonarsi

Intérêt de l'utilisation du pindolol dans le traitement des dépressions : revue de la littérature - 17/02/08

Doi : ENC-9-2003-29-4-0013-7006-101019-ART7 

G. BROUSSE [1],

A. SCHMITT [1],

I. CHEREAU [1],

A. ESCHALIER [2],

C. DUBRAY [2],

P.-M. LLORCA [1]

Mostrare le affiliazioni

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 13
Iconografia 2
Video 0
Altro 0

La correction des 2 points faibles des antidépresseurs, à savoir un délai d'action retardé et un pourcentage élevé de résistance au traitement constitue un enjeu majeur dans le traitement de la dépression. Sur la base d'hypothèses physiopathologiques confirmées par des travaux expérimentaux, 6 études ouvertes et 12 études fermées ont étudié l'effet de l'association du pindolol (antagoniste des récepteurs 5HT 1A ) à un traitement antidépresseur tant dans le raccourcissement du délai d'action que dans l'augmentation de son efficacité. Si les études ouvertes concluent à un raccourcissement du délai d'action, les données sont contradictoires en ce qui concerne la potentialisation de l'efficacité. Les études en aveugle, quant à elles, concluent majoritairement à un raccourcissement du délai d'action mais sont moins tranchées en ce qui concerne l'augmentation de l'efficacité. L'inhomogénéité des résultats en ce qui concerne notamment les dépressions résistantes peut être expliquée par des éléments liés à l'histoire de la maladie dépressive des patients. Ainsi, les patients dépressifs aux antécédents d'épisodes dépressifs antérieurs seraient de moins bons répondeurs à l'association pindolol-antidépresseur et surtout si cet antidépresseur a été utilisé sans succès lors des épisodes antérieurs, voire lors de l'épisode actuel (dépressions résistantes).

Interest of the use of pindolol in the treatment of depression : review

The principal stakes of depression treatment are to accelerate and enhance the clinical effects of antidepressant drug. The onset of antidepressant action of Serotonin (5HT) selective reuptake inhibitors (SSRIs) was attributed in part to the decrease in firing activity of serotonin neurons produced by the activation of raphe 5HT 1A autoreceptors at the time of treatment initiation. Pindolol, an antagonist at somatodendritic pre-synaptic 5HT 1A receptors has been investigated as a potential accelerator or potentialisator of antidepressant response. Six open label studies and 12 controlled studies were identified for revue. The first open-label pilot study was conducted by Artigas et al. [4]. They showed promising results with pindolol, both in the acceleration of antidepressant response and in improving the efficacy of antidepressant. On the basis of these results five open-label studies were conducted [7] [11] [13] [22] [47]. The open label studies suggest that pindolol accelerate the antidepressant response of serotoninergics therapeutics. The augmentation of antidepressant response was not clearly demonstrated by these studies particularly in the treatment of refractory depression. For example, Dinan et Scott [22]that found the addition of pindolol in association with SSRI therapy had a poor efficacy. In the twelve controlled studies, 4 tried to underscore the shortening of the onset and the augmentation of efficacy of SSRI by pindolol [Berman et al. [8], Maes et al. [31], Perez et al. [36], Tome et al. [46]], 3 tried to underscore shortening of the onset [Bordet [16], Zanardi [48] [49]] and 3 tried to underscore the augmentation of efficacy [Maes et al. [30], Moreno et al. [33], Perez et al. [37]]. One study tried to underscore the augmentation of efficacy of sleep deprivation by pindolol and another one the shortening of the onset of ECT. Six studies included depressive resistant patients [30] [31] [33] [37] [43] [44]. Three studies were carried out with fluoxetine [8] [31] [36], 1 with fluvoxamine [49], 3 with paroxetine [17] [46] [48], 1 with trazodone [30]. Two studies were investigated with several antidepressant treatments [33] [37]. The results of the studies indicate one acceleration of antidepressant response in 6 studies [16] [36] [43] [46] [48] [49], one augmentation of efficacy in 5 studies [30] [31] [36] [44] [48]. Two studies clearly demonstrate that pindolol may augment and accelerate antidepressant response [36] [48]. Three studies did not confirm these observations [8] [33] [37]. Several points can be examined. For pindolol : 3 authors [16] [31] [36]have demonstrated that the effect of pindolol did not rely upon small antidepressant effect mediated by b-blockers properties, because anxiety was not predominantly improved by pindolol plus SSRI while depressive symptoms were clearly improved. On the basis of data issues from recent positron emission tomography (PET) studies, several authors suggested that the dose of pindolol used in most clinical trials (3 x 2,5 mg day-1) might be insufficient to induce a substantial occupancy of 5-HTA receptors (Rabiner et al. [38] [39]. It is possible that higher doses will show a more evident benefit. On the whole, pindolol seemed to be well tolerated. Adverse effects most commonly reported were increased irritability, insomnia and nausea. Pindolol had poor adverse effects in cardiovascular functions. The variation of the results of the controlled studies can be explained by different points : Firstly by difficulty to determine good criterion of resistance. The most simplistic definition of treatment resistance is the failure to achieve and sustain euthymia with adequate antidepressant treatment [24]. Secondly by the fact that depressive patients who present antecedents of depressive illness seem to be worst responders to the association pindolol/serotoninergic antidepressant than patients suffering of first episode of depression. We observed one antecedent of depression in the group of resistant patients who were good responders to the association pindolol/antidepressant therapy [30] [31]. We observed three anterior episodes of depression in negatives studies of the association pindolol/antidepressant therapy [37]. Thirdly by the fact that the failure of the antidepressant treatment at the time of earlier (or actual) episode seems to be a criterion for less responsiveness to the association of this antidepressant treatment with pindolol. In fact, the open label studies who demonstrated efficacy of the association between pindolol and serotoninergic therapy in major resistant depression were realized with new antidepressant molecule for the episode. Other controlled trials could confirm these facts. Most of the studies failed to retrace clearly the historicity of depression, and it may be interesting in future investigations to analyze the response of the association compared to the status of the patient with the antidepressant therapy. Further perspective could be envisaged especially in the utilization of pindolol for the treatment of pathologies which are usually treated with a serotoninergic antidepressant therapy. For example, the antagonist 5HT 1A Way 100635 was experimented with success in animals in order to augment the efficacy of clomipramine in the treatment of chronic pain [1]. In other respects several psychopharmacogenetics studies could be investigated to examine, for instance, the role of the 5-HT transporter and its implication in the response to pindolol and antidepressant association. In summary, pindolol accelerates, and in some cases enhances the clinical action of antidepressant drugs. It appears that this augmentation strategy has more limited effect on treatment resistant patient but there is experimental evidence for using higher doses in future augmentation trial.


Mots clés : Antagoniste 5HT 1A ; , Délai d'action ; , Dépression ; , Pindolol ; , Résistance ; , Sérotonine.

Keywords: Antagonist 5HT 1A ; , Depression ; , Onset of action ; , Pindolol ; , Serotonin.


Mappa



© 2003 Elsevier Masson SAS. Tous droits réservés.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 29 - N° 4

P. 338-350 - Settembre 2003 Ritorno al numero
Articolo precedente Articolo precedente
  • Déficience auditive et troubles psychopathologiques chez l'enfant et l'adolescent
  • D. BAILLY, M.-B. DE CHOULY DE LENCLAVE, L. LAUWERIER
| Articolo seguente Articolo seguente
  • Les facteurs étiologiques du trouble d'anxiété généralisée : état actuel des connaissances sur les facteurs psycho-sociaux
  • P. GOSSELIN, B. LABERGE

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.